Ulcer Hemorrhage Clinical Trial
Official title:
A Double-blind, Randomized, Placebo Controlled Trial of Misoprostol for Healing of Small Bowel Ulcers in Aspirin Users With Small Bowel Bleeding (MISO-SB Study)
ASA is the most commonly drug used worldwide for prevention of cardiovascular diseases.
However, ASA is increasingly recognized as a culprit for small bowel bleeding. Small bowel
bleeding is notoriously difficult to diagnose because it is beyond the reach of conventional
endoscopy. The advent of wireless, video capsule endoscopy has revolutionized the
visualization of small bowel. Capsule endoscopy is a pill that contains a tiny camera for
capturing pictures of the small bowel after being swallowed. Currently, capsule endoscopy is
a recommended noninvasive approach of identifying the source of small bowel bleeding.
Management of ASA-associated small bowel bleeding is a major clinical challenge since there
is not a single effective treatment for small bowel ulcer, and continuation of ASA increases
the risk of recurrent small bowel bleeding. However, discontinuation of ASA exposes patients
to thrombotic complications. Suppression of prostaglandin synthesis is an important mechanism
of ASA-induced small injury. Consistent with this theory, preliminary data from a case series
showed that misoprostol, a prostaglandin analog, healed small bowel ulcers in ASA users.
However, the efficacy of misoprostol in healing ASA-associated small bowel ulcers has not yet
been confirmed by prospective randomized trials.
This double-blind clinical trial tests the hypothesis that misoprostol can heal small bowel
ulcers in Aspirin users complicated by small bowel bleeding.
ASA is the most commonly drug used worldwide for prevention of cardiovascular diseases.
However, ASA is increasingly recognized as a culprit for small bowel bleeding. The latter
condition manifests as overt bleeding (i.e., passing black or bright red stool) or occult
blood loss (i.e., normal stool but progressive decrease in hemoglobin level), with normal
findings in the stomach and colon. Small bowel bleeding is notoriously difficult to diagnose
because it is beyond the reach of conventional endoscopy. The advent of wireless, video
capsule endoscopy has revolutionized the visualization of small bowel. Capsule endoscopy is a
pill that contains a tiny camera for capturing pictures of the small bowel after being
swallowed. Currently, capsule endoscopy is a recommended noninvasive approach of identifying
the source of small bowel bleeding.
The problem of small bowel bleeding is increasingly recognized, partly because the use of ASA
is rising. In a regional hospital in Hong Kong, we diagnose about 100 cases of ASA-associated
small bowel overt bleeding/occult blood loss each year. In a prospective cohort study we
found that among ASA users with a history of small bowel bleeding, the risk of recurrent
small bowel bleeding is 4 times higher in patients who continued to use ASA than in those who
discontinued ASA.
Management of ASA-associated small bowel bleeding is a major clinical challenge for two
reasons. First, there is not a single effective treatment for small bowel ulcer. Unlike
peptic ulcers, injury to the small bowel is acid-independent. Thus, conventional stomach
protective drugs cannot heal or prevent small bowel ulcers in ASA users. Neither can
switching to other non-ASA anti-platelet drugs reduce the risk of bleeding. Second, we have
shown that continuation of ASA increases the risk of recurrent small bowel bleeding. However,
discontinuation of ASA exposes patients to thrombotic complications. Currently, there is no
local or international guideline on the management of ASA-associated small bowel bleeding.
Suppression of prostaglandin synthesis is an important mechanism of ASA-induced small injury.
Consistent with this theory, preliminary data from a case series showed that misoprostol, a
prostaglandin analog, healed small bowel ulcers in ASA users. However, the efficacy of
misoprostol in healing ASA-associated small bowel ulcers has not yet been confirmed by
prospective randomized trials.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03611504 -
Hemospray in Gastrointestinal Bleeding: A Real-life Multicenter Cohort
|
||
Completed |
NCT01278550 -
Prevention of Recurrent Ulcer Bleeding in High-risk Users of Low-dose Aspirin
|
N/A | |
Completed |
NCT04239118 -
New Technologies for Endoscopic Treatment of Bleeding Gastroduodenal Ulcers
|
N/A | |
Completed |
NCT05227833 -
Vonoprazan Efficacy to Prevent Post Variceal Band Ligation Ulcer
|
Phase 3 |